LY2157299

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

LY2157299 (also known as Galunisertib) is an investigational drug currently being studied in clinical trials for certain types of cancer, including rectal cancer. It is being tested in combination with standard treatments like chemoradiation (chemotherapy and radiation therapy). The goal of the trials is to see if LY2157299 can improve the effectiveness of these standard treatments, potentially leading to better outcomes for patients. Specifically, researchers are looking at how it might affect the immune system's response to the tumor, aiming to increase the activity of immune cells (T cells) within the tumor. It is not yet approved for use in colorectal cancer.

Mechanism of Action

LY2157299 is being investigated for its potential to enhance the immune response against cancer cells. Clinical trials suggest it may work by improving the activity and infiltration of effector T cells into the tumor. The specific molecular target is being characterized in clinical trials.

Side Effects

LY2157299 is an investigational drug And its side effects are still being evaluated in ongoing clinical trials. The most informative trial (NCT02688712) describes a safety lead-in period Indicating that safety is a primary focus. Specific side effects observed in trials are not detailed in the provided information But as with many cancer treatments Potential side effects could include fatigue Gastrointestinal issues And effects related to the immune system. Patients participating in trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02688712 Phase 2
Active, not recruiting
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
781 trials
Leucovorin
Other Medications
641 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.